About us
Founder's Message
Our goal is not business, but to remain patient-focused.
Dear everyone,
I am Chihaya Kakinuma, the founder of HOIST Corp.
We have embodied the meaning, “raising the sails” in the name of the organization.
I believe that we have completed the preparation to “hoist the sail” into the wide
oceans, having learned from various companies, universities and research groups.
that one of my few strengths is realizing my weaknesses. I therefore do not hesitate to
request help from my colleagues, and fortunately, I have been surrounded by
colleagues who could support me. One of my most important values is to connect with
people. By doing this, I will do my best to meet your expectations, and achieve the results expected of HOIST Corp.
The philosophy of HOIST Corp. is to remain committed to the patients. The strengths of
this commitment is not related to the size of the company. Unmet medical needs
continue to exist, and many patients continue tosuffer. Our goal is to continue to
prioritize the patients, and not (just) succeeding in business. While it is likely that there
are various processes and secrets of successes in drug discovery, HOIST Corp. will
not hesitate to deviate from conventional practices in the pursuit of breakthroughs.
HOIST Corp. promises to advance drug discovery in our unique way, in order to
continue to prioritize, and to help the patients.
The dream is to connect the revolutionary discovery in basic research with the clinics.
To create revolutionary medicines with new modalities for cancer patients, who do not
have enough treatment options.
We have realised this dream in HOIST Corp. a biopharmaceutical company originating
from The University of Osaka.
Company Profile
Company Name
HOIST Corp.
Date of Establishment
May 30, 2019
Capital
133,999,764 JPY
Headquarters
New Erimo Bldg. 8F, 2-2-1, Sembanishi, Minoh-shi, Osaka, 562-0036, JAPAN
Wakayama Medical University Collaborative Research Laboratory
Center for Next-Generation Medicine Research, 401, Kimiidera Campus, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama 641-8509, Japan
Business
Anti-cancer drug development, Drug discovery support using PDC/PDX models
Management Team
Representative Director
Chihaya Kakinuma
Executive Officers
Koji Abe
Yasuhiro Shimada
Directors
Hiroaki Adachi
Akira Uotani
Auditor
Tomoyuki Mokuo
Advisors
Kazutake Tsujikawa, Former Professor, Graduate School of Pharmaceutical Sciences, The University of Osaka
Takefumi Doi, Former Professor, Graduate School of Pharmaceutical Sciences, The University of Osaka
Takuo Ogihara, Professor, Faculty of Pharmaceutical Sciences, Tokyo University of Science
- Click image to enlarge
- PDF Organization Chart
